Skip to content

A.L.P.S. Clavicle Plating System PMCF

A.L.P.S. Clavicle Plating System for Clavicle Fracture Fixation Post-Market Follow-up Study (Implants and Instrumentation)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05327959
Enrollment
98
Registered
2022-04-14
Start date
2022-05-13
Completion date
2027-03-01
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clavicle Fracture, Clavicle Injury

Keywords

clavicle

Brief summary

A commercially available product clinical study which aims to confirm the safety, performance, and clinical benefits to the patient of the ALPS Clavicle Plating system for both the implant itself and the instrumentation used during surgery.

Detailed description

The objectives of this observational, prospective study with optional retrospective enrollment are to confirm safety, performance and clinical benefits of the A.L.P.S Clavicle Plating System and its instrumentation by analysis of fracture healing, functional outcome and adverse events. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events including re-operations. Relation of the events to implant, instrumentation and/or procedure should be specified. The performance will be evaluated by assessment of fracture/osteotomy healing and functional outcome of all enrolled study subjects.

Interventions

DEVICEClavicle open reduction and internal fixation

Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patient must be 18 years of age or older. * Patient must have a clavicle fracture requiring surgical intervention and be eligible for fixation by locking plate and screws. * Unilateral or Bilateral fractures. * Patient must be capable of understanding the doctor's explanation, following doctor's instruction, is able to and willing to complete the protocol required follow-up. * Patient must have a signed IRB/EC approved informed consent.

Exclusion criteria

* Active infection. * Patients presenting conditions including blood supply limitations, insufficient quantity or quality of bone. * Patients with mental or neurologic conditions who are unwilling or incapable of giving proper informed consent, following postoperative care instructions. * Foreign body sensitivity where material sensitivity is suspected, testing is to be completed prior to implantation of the device. * Patient is a current alcohol or drug abuser * Patient is a prisoner * Patient known to be pregnant or breast feeding * Likely problems with maintaining follow-up program (e.g. patient with no fixed address, long distance, plans to move during course of study) * Not expected to survive the duration of the follow-up program

Design outcomes

Primary

MeasureTime frameDescription
Number of subjects with fracture healing12 monthsNumber of subjects with fracture healing will be assessed through 12 months follow-up. Radiologic fracture healing is defined as: Bridging callus or no visible fracture lines on AP and 15-45° cephalic oblique radiographs.

Secondary

MeasureTime frameDescription
Frequency and Incidence of Adverse Events (Safety)12 monthsMonitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
Range of Motion - Total shoulder motion12 monthsRange of Motion (affected and contralateral), Forward elevation (maximum arm-trunk angle), External rotation (arm comfortably at side), External rotation (arm at 90 degrees of abduction), Internal rotation (thumb to back) spinous process, Cross-body adduction (antecubital fossa to opposite acromion (cm)
Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 12 months follow-up12 monthsThe ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.
Euroqol Patient Quality of life measured at 12 months follow-up (EQ-5D-5L)12 monthsThe EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.

Countries

Spain, United States

Contacts

STUDY_DIRECTORHillary Overholser

Zimmer Biomet

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026